Human-centered programming is increasingly offered as a solution to public health challenges, but what does it really mean? This simple graphic shows some of the core elements in the equation.
Human-Centered Design: How it adds up
Using HCD to Solve a Problem
This graphic describes, in three parts, how to use human-centered design could be used to help with the low uptake of VMMC.
AVAC Report 2018 & HIV R4P
In this episode of Px Pulse, Ntando Yola, a veteran advocate and part of the Coalition to Accelerate and Support Prevention Research (CASPR) shares his advocacy priorities for R4P and beyond. But first, AVAC’s Emily Bass talks about the just-launched 2018 annual report from AVAC, this year titled No Prevention, No End!
Video Series: Lessons from the Field
Six short videos spotlight lessons learned at PrEP demonstration projects run by LVCT Health in Kenya. The series explores key issues from the introduction of PrEP and managing symptoms to adherence and the role of support groups.
Prevention Paradigm, 2017-beyond
While several different interventions exist for contraception, there aren’t yet a full array of options for HIV prevention. Choices matter. This graphic appears in AVAC Report 2017: Mixed messages and how to untangle them.
The UNAIDS 10-Point Plan for Making Progress on Prevention
The UNAIDS 10-point plan for making progress on prevention omits elements of the “research-to-rollout” continuum, and leaves the definition of prevention out—focusing on the “how” rather than the “what”. This graphic appears in AVAC Report 2017: Mixed messages and how to untangle them.
Fighting HIV Drug Resistance in Uganda
AVAC Fellow Moses Supercharger has this primer on the upward trend of HIV drug resistance in Uganda, with action items for advocates.
PrEP 101 Presentation from US Women & PrEP Working Group
Created by the US Women and PrEP Working Group, this PowerPoint is intended to help make quality, basic presentations on PrEP to community members.
Layers of Biomedical HIV Prevention Trial Stakeholders
Various stakeholders may influence or be affected by a biomedical HIV prevention trial. Stakeholders include trial participants and other community stakeholders as well as a broader range of national and international stakeholders.
Excerpted from the Good Participatory Practice (GPP) Guidelines, which provide trial funders, sponsors, and implementers with systematic guidance on how to effectively engage with all stakeholders in the design and conduct of biomedical HIV prevention trials. More at avac.org/gpp.
PrEP for MSM in Africa: Meeting Summary and Next Steps
Advocates gather in South Africa for the continent’s first PrEP and MSM consultation to chart a path for PrEP access. See the report summary with links to presentations and country plans.